Home » Business, Health & Medicine, Pharmaceuticals & Biotech, World » Pulmonary Arterial Hypertension Market Growing at 3.20% CAGR to 2024 – MarketIntelReports
“The US market is expected to grow the fastest of the three regions, recording a CAGR of 3.70% and generating around 75% of global sales in 2024.”
Pulmonary Arterial Hypertension Market: the US fastest growing region through 2024.

The pulmonary arterial hypertension is a condition where the blood pressure in the pulmonary artery increases and will lead to dizziness, shortness of breath and other symptoms. With the rise in population and increasing illnesses among people, it has been noted that the patients with pulmonary hypertension symptoms are rising which boosts the demand of pulmonary hypertension treatment in the Pulmonary Arterial Hypertension Market.

Pulmonary Arterial Hypertension Market Estimations:

It is estimated in the Pulmonary Arterial Hypertension Market, the 2014 sales for pulmonary arterial hypertension (PAH) at approximately $3.45 billion across the 7MM covered in the report, which include the US, 5EU (France, UK, Italy, Germany and Spain) and Japan.

The Pulmonary Arterial Hypertension Market will grow moderately at a CAGR of 3.20% during the 10-year forecast period, generating sales of approximately $4.75 billion at the end of 2024. The US market is expected to grow the fastest of the three regions, recording a CAGR of 3.70% and generating around 75% of global sales in 2024.

The major drivers for this growth across the 7MM will be the launch of Actelion’s Uptravi and the increased use of double and triple combination therapy. The rise of elderly population around the world and growth of pulmonary hypertension symptoms will determine the demand for treatment and drugs sales in this market.

 

Complete research on Pulmonary Arterial Hypertension Market available at http://www.marketintelreports.com/report/gdhc050poa/opportunityanalyzer-pulmonary-arterial-hypertension–opportunity-analysis-and-forecast-to-2024

 

Key findings of the Pulmonary Arterial Hypertension Market:

In the Pulmonary Arterial Hypertension Market, the major drivers for growth across the 7MM in the PAH market during the forecast period will be the launch of the first-in-class prostacyclin receptor agonist, Uptravi marketed by Actelion and the increased use of combination therapy.

Uptravi has a promising future as a second-line therapy in the PAH market, and has the potential to displace oral treprostinil’s market position.

In the Pulmonary Arterial Hypertension Market, the highest revenue generators in the 7MM market at the end of 2024 will be Actelion’s Veletri, Opsumit and Uptravi and Bayer’s Adempas. The greatest unmet need in the PAH disease space is the need to develop novel drugs with curative or disease-stabilizing properties.

Low disease awareness, declining population in the 5EU (France, Germany, Italy, Spain and UK) and Japan, high cost of drugs and patent expirations of branded drugs are the major barriers for growth in the PAH market during the forecast period.

Order a copy of Pulmonary Arterial Hypertension Market report @ http://www.marketintelreports.com/purchase.php?id=gdhc050poa

Prominent companies in the Pulmonary Arterial Hypertension Market:

Some of the prominent companies in the Pulmonary Arterial Hypertension Market that manufacture PAH drugs and treatment in the global market at huge scale are as follows:

  • Pfizer
  • Eli Lilly
  • Bayer
  • Gilead United Therapeutics
  • Toray Pharmaceuticals

The Pulmonary Arterial Hypertension Market is a potential market with high scope in medical industry all across the globe through 2024. This market is expected to have high growth in many regions owing to the rise of population and improvising healthcare facilities. This market is expected to witness moderate demand for drugs in various regions depending on the supply capacity and demand through 2024.

Check research sample here http://www.marketintelreports.com/pdfdownload.php?id=gdhc050poa

 

On a related note, another research on

Pulmonary Arterial Hypertension – Pipeline Review, H1 2016 @ http://www.marketintelreports.com/report/gmdhc7707idb/pulmonary-arterial-hypertension–pipeline-review-h1-2016

Pulmonary Arterial Hypertension-Pipeline Insights, 2016 @ http://www.marketintelreports.com/report/dipr2016552/-pulmonary-arterial-hypertensionpipeline-insights-2016

About Us:

MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.

MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

 

Media Contact
Company Name: MarketIntelReports
Contact Person: Mayur S.
Email: sales@marketintelreports.com
Phone: 1-302-261-5343
Address:2711 Centerville Road, Suite 400
City: Wilmington
State: Delaware
Country: United States
Website: www.marketintelreports.com

Comments are closed.